On June 27, 2025, Innovent Biologics, Inc., a leading biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for oncology, autoimmune, cardiovascular, and metabolic diseases, announced that China's National Medical Products Administration (NMPA) approved Mazdutide, the worlds first dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity
Shouldnt humans be treated with the same level of respect and care
Crohns disease or celiac disease
Because of its ability to dramatically suppress appetite and promote significant weight loss, Tirzepatide is often referred to as a " skinny shot " in the same vein as Semaglutide
Conversely, patients with Addisons disease, characterized by insufficient cortisol production, often suffer from hypoglycemia, which can impair liver function
Beth Levine Author Beth Levine is an award-winning health writer whose work has appeared in The Washington Post, The New York Times, O: The Oprah Magazine , Woman's Day , Good Housekeeping , Reader's Di...
